Interferon treatment of hepatitis C virus (HCV) infection after liver transplantation
hepatitis, 36% acute cellular rejection, 6% chronic rejection, and 9% combined findings. Median time to liver enzyme resolution was 77.5 days (IQR, 31.5;126). After diagnosis, hospitalizations, steroid-induced hyperglycemia, and infection occurred in a higher percentage of cases vs controls (33% vs 7.5%, 21% vs 1.5%, 9% vs 0%; all P < .05). Only one IGD patient died and none required retransplant. A multivariate regression analysis found that liver enzyme elevations during and soon after DAA therapy completion correlated with subsequent IGD. In conclusion, while DAA-IGD is uncommon, liver enzyme elevations during or after DAA therapy may be a sign of impending IGD. These indicators should guide clinicians to diagnose and treat IGD early before the more deleterious later clinical presentation.
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antibiotic: antiviral, clinical research/practice, immunosuppression/ immune modulation, infection and infectious agents-viral: hepatitis C, infectious disease, liver allograft function/ dysfunction, liver disease: infectious, liver transplantation/hepatology, rejection treated was 189 (Northwestern), 73 (Mount Sinai), 262 (UCSF), 164 (Penn), 227 (Emory), and 63 (Columbia) for a total of 978. For IGD patient identification, the local investigator reviewed each patient's electronic medical record for any biopsies performed either during or after DAA therapy and assessed each final pathology read for evidence of acute rejection, other immune-mediated hepatitis (eg, plasma cell), or chronic rejection. After the patients were locally identified, two HCV-positive DAA-treated controls (non-IGD) who did not have increased liver chemistry tests requiring a biopsy after therapy were manually selected and matched by year of LT.
This matching was done to maintain homogeneity in post-LT management and clinical practices (eg, immunosuppression [IS] and DAA regimens), which can otherwise vary by time and providers. It was not required that the controls had comparative liver biopsies after DAA therapy, as these were not routinely performed across all study centers, nor were controls matched on specific DAA combination received.
The following were exclusion criteria for patients and controls: treatment failure with prior DAA therapy pretransplant, evidence of other etiology of graft dysfunction (eg, biliary/vascular/drug induced), diagnosis of recurrent hepatocellular carcinoma, and lack of follow-up or incomplete data on variables and outcomes.
| Variables
The principal investigators (CC, JL) and statistician (AY) assembled and analyzed a unified database incorporating the separately estab- 
| Statistical methods
Simple descriptive statistics were used to summarize demographic characteristics and clinical measures. Pearson's chi-square test was applied to assess associations between group and categorical measures. Fisher's exact test was used when expected cell counts were less than 5 for a given cross tabulation. Continuous variables were compared across groups using t tests for normally distributed data and Wilcoxon rank sum tests when statistical assumptions (ie, normality) were uncertain. The distribution of clinically relevant variables such as age, reduction IS, and undetectable IS was compared between the cases and controls. Any potential confounder that showed significance at P < .05 level was included in a multiple logistic regression model. We did not include sex and prior interferon in the multiple regression model because they are not considered as clinically relevant as predictors on therapy. Because liver enzyme elevations during and soon after DAA therapy were found to be the only predictors of future IGD on univariate analysis, we performed multiple logistic regressions with liver tests results or the change of the test results as predictors. Odds ratios and area under the curve (AUC) were reported from the models. Because the purpose of the study is to identify associated factors for DAA-IGD, as opposed to developing a prediction model for the outcome, we did not evaluate the model performance in terms of prediction ability, sensitivity, or specificity. All analyses assumed a 5% level of significance and were performed using R: A language and environment for statistical HCV genotype, 1, n (%) 5 (15) 12 (18) .706
History of autoimmune disease, n (%)
.549
History of any rejection, n (%) 6 (18) 12 (18) >.999
Any positive autoantibody 2 (6) 13 (20) .074
At start of DAA therapy 
| RE SULTS

| Participants
Six major liver transplant centers comparable in size and practice (33 patients/978 total) with a range of 1.1% to 6.3% across centers.
We included the centers as a variable in the overall analysis and found no statistical difference in the percentage of cases among the six centers (P = .110). For the risk factor and outcome comparative analysis, 66 DAA-treated non-IGD controls were included in the study. Infections, n (%) 3 (9) 0 .035
| Descriptive and outcomes data
Steroid induced hyperglycemia, n (%)
Death n (%)
TA B L E 2 Clinical presentation and outcomes of DAA-IGD other differences were noted between cases and controls, including immunosuppressive regimen, trough levels, and reduction in immunosuppression or undetectable levels during or after DAA therapy, the type of DAA therapy used, and SVR rates. As such, we identified that elevations in liver chemistry tests during and after DAA treatment were significantly associated with Change from baseline to post-DAA treatment toimmune markers, however, were not found to be associated risk factors. Furthermore, although there was a suspicion that rejection after DAA therapy may be related to improved liver function and lower immunosuppression levels with HCV clearance, 18 we did not find a correlation.
Although the mechanisms for induction of graft inflammation with IFN are known, we do not yet know the mechanism of injury with DAAs, as this therapy is not known to directly lead to immune activation like IFN. It has been described that chronic HCV infection leads to impairment in innate and adaptive immune responses.
As DAA therapy has been found to reverse some of these immune disturbances indirectly through viral clearance, 19,20 a parallel can be made with the immune reconstitution inflammatory syndrome occurring after highly active antiretroviral therapy in patients with HIV, which may result in severe autoimmune hepatitis.
21,22
Persistent lymphoid aggregates that are typically seen in chronic hepatitis C have been noted after SVR. 23 The role of these findings in the development of DAA-IGD is not yet known and may be worthwhile to investigate in future studies. In this study, no differences in baseline characteristics were observed in regard to HCV (genotype, viral load upon initiation of treatment, etc) or type of DAA therapy. All of the cases and controls in our study achieved SVR after completion of DAA therapy. Therefore, even though chronic HCV infection itself may lead to relative immunosuppression, viral clearance and subsequent immune reconstitution were not obviously associated with liver injury, although this pathway is still suspected.
There are limitations to our study. Because of the retrospective case-control design, selection bias is a possibility. Additionally, untested variables unaccounted for may be confounding factors for the differences noted. Despite the multicenter design of our study, 
CO N FLI C T S O F I NTE R E S T
The authors of this manuscript have conflicts of interest to disclose as 
R E FE R E N C E S
